Skip to main content

Table 1 Clinical, echocardiographic and CMR characteristics of diabetic versus nondiabetic HFpEF patients

From: Diabetic phenotype and prognosis of patients with heart failure and preserved ejection fraction in a real life cohort

  Nondiabetic N = 113 (62%) Diabetic N = 70 (38%) p-value
Age (years) 80 ± 8 76 ± 9 0.002
Female (n, %) 71 (63%) 42 (60%) 0.70
Body mass index (kg/m2) 27 ± 6 31 ± 6 0.001
NYHA III–IV (n, %) 60 (53%) 27 (39%) 0.056
Hospitalized for HF at inclusion (n,%) 73 (65%) 43 (61%) 0.53
Atrial fibrillation (n, %)
 History 78 (69%) 37 (53%) 0.028
 At inclusion 57 (50%) 26 (37%) 0.079
Ischemic cardiomyopathy (n, %) 27 (24%) 33 (47%) 0.001
Smoking (n, %) 50 (45%) 27 (39%) 0.42
Hypertension (n, %) 105 (93%) 67 (97%) 0.23
Hypercholesterolemia (n, %) 66 (59%) 49 (70%) 0.13
Sleep apneas (n, %) 8 (7%) 12 (18%) 0.032
COPD (n, %) 12 (11%) 7 (10%) 0.88
Medication
 Loopdiuretics (n, %) 73 (65%) 51 (73%) 0.25
 MRA (n, %) 19 (17%) 13 (19%) 0.76
 Beta blockers (n, %) 77 (68%) 41 (59%) 0.19
 ACE inhibitors/ARB (n, %) 78 (69%) 46 (66%) 0.64
Biology
 eGFR (ml/min/1.73m2) 58 ± 22 50 ± 24 0.026
 Hemoglobin (g/dL) 12 ± 2 11 ± 2 0.041
 NT-proBNP (pg/mL) 1937 [1040–3775] 1745 [955–3710] 0.56
 Troponin (pg/mL) 22 [13–37] 31 [17–42] 0.034
Echocardiography
 Indexed LA volume (mL/m2) 46 ± 19 45 ± 16 0.67
 LV ejection fraction (%) 62 ± 7 61 ± 8 0.35
 E wave velocity (mm/s) 91 ± 32 97 ± 26 0.23
 Septal E/e’ 19 ± 9 20 ± 7 0.17
 TAPSE (mm) 19 ± 5 18 ± 5 0.40
 eSPAP (mmHg) 43 ± 11 45 ± 15 0.27
CMR N = 94 N = 57  
 CMR indexed LA Volume (mL/m2) 70 ± 31 62 ± 25 0.12
 CMR indexed LV EDV (mL/m2) 72 ± 18 74 ± 17 0.37
 CMR LV ejection fraction (%) 62 ± 8 62 ± 9 0.62
 CMR indexed LV mass (g/m2) 66 ± 18 71 ± 14 0.07
 CMR RV ejection fraction (%) 56 ± 8 58 ± 8 0.41
 CMR indexed RV EDV (mL/m2) 79 ± 25 83 ± 27 0.36
 ECV > 33% 34 (36%) 28 (53%) 0.05
  1. Continuous variables are expressed as mean ± 1 standard deviation (SD) and categorical variables as count and proportion. P-values are derived from independent sample t-test or Chi square test when appropriate
  2. NYHA: New York Heart Association; COPD: chronic obstructive pulmonary disease; GFR: glomerular filtration rate estimated by CKD-epi; MRA: mineralocorticoid receptor antagonist; ACE: angiotensin-converting enzyme; ARB: angiotensin II receptor blockers LV: left ventricle; LA: left atrium; TAPSE: tricuspid annular plane systolic excursion; eSPAP: estimated systolic pulmonary artery pressures; CMR: cardiac magnetic resonance; EDV: end diastolic volume; RV: right ventricle; ECV: extracellular volume estimated by T1 mapping